RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--May 10, 2006--Tranzyme Pharma announced today that it has successfully completed a Phase I clinical trial of its first drug candidate, TZP-101, a new chemical entity originating from the Company’s proprietary small molecule macrocyclic chemistry technology. TZP-101 is a selective ghrelin receptor agonist with potent gastroprokinetic properties that represents the first in its class to enter into a clinical trial. Tranzyme Pharma is developing TZP-101 as a mechanism-based therapy for post-operative ileus (POI) and other gastrointestinal (GI) motility disorders. The Phase I study demonstrated that TZP-101 is safe and well tolerated in healthy subjects and that the safety and pharmacokinetic profile of the compound support further clinical development.
